MedTrace Logo

Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding

NCT00731601 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2009-04-07

No results posted yet for this study

Summary

A large dose of PPI is effective in preventing peptic ulcer rebleeding. The investigators hypothesize that 40 mg/q6h pantoloc is equivalent to 8mg/h pantoloc in preventing rebleeding.

Conditions

  • Peptic Ulcer Hemorrhage

Interventions

DRUG

pantoprazole

pantoprazole 40 mg/q6h IV infusion for three days

DRUG

pantoprazole

pantoprazole 8 mg/h IV infusion for three days

Sponsors & Collaborators

  • Lotung Poh-Ai Hospital

    lead OTHER

Principal Investigators

  • Hwai-jeng Lin, M.D. · Lotung Poh-Ai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-03-31
Completion
2009-04-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00731601 on ClinicalTrials.gov